Complete Sequencing of Plasmids Containing blaOXA-163 and blaOXA-48 in Escherichia coli Sequence Type 131.
OXA-48-like enzymes have emerged as important extended-spectrum β-lactamases/carbapenemases in Escherichia coli sequence type 131 (ST131). We report the structures of the first fully sequenced blaOXA-163plasmid and of two other blaOXA-48plasmids in this lineage. blaOXA-163was located on a 71-kb IncN plasmid with other resistance genes. blaOXA-48was present on IncL/M plasmids, genetically similar to other blaOXA-48plasmid sequences, and consistent with interspecies/interlineage spread. The presence of blaOXA-48-likegenes on epidemic plasmids in ST131 is of concern.
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom nicole.stoesser@ndm.ox.ac.uk.
Nicole
0000-0002-4508-7969
N
Stoesser
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Anna E
AE
Sheppard
Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada.|Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Gisele
G
Peirano
Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Robert
R
Sebra
Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Tarah
T
Lynch
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Luke
L
Anson
Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Andrew
A
Kasarskis
Clinical Microbiology, Merck and Co., Inc., Rahway, New Jersey, USA.
Mary R
MR
Motyl
Modernizing Medical Microbiology Consortium, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Derrick W
DW
Crook
Division of Microbiology, Calgary Laboratory Services, Calgary, Alberta, Canada.|Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.|Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.|Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada.|Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa.
Johann D
JD
Pitout
D024881:Drug Resistance, Bacterial / Q000235:genetics; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics*; D029968:Escherichia coli Proteins / Q000235:genetics* / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D010957:Plasmids / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
D029968:Escherichia coli Proteins; D001618:beta-Lactamases; C000622541:beta-lactamase OXA-163, E coli; C000601047:beta-lactamase OXA-48, E coli